A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia
Blood · 2025
DOI: 10.1182/blood.2024025440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2025. Verfasst von Aïda Falgàs und 34 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Madrid, Spain. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Hepatitis A Virus Cellular Receptor 2, T-Lymphocytes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19) T-cell therapy, >50% of patients relapse within a year. Both leukemia cell–intrinsic factors favoring immune escape and poor CAR T-cell persistence contribute to clinical failure. Moreover, the expression of immune checkpoint receptors (ICRs) and their ligands within the bone marrow (BM) microenvironment may contribute to leukemia progression and therapy resistance. Here, we characterized the expression of ICRs and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells (MSCs) from B-ALL BM samples at diagnosis and relapse, comparing them with age-matched healthy BM controls. Our findings reveal a significantly upregulated expression of TIM-3 in T cells and its ligand, galectin-9, in both blasts and MSCs throughout disease progression. The expression of galectin-9 in B-ALL blasts and TIM-3 in CAR19 T cells negatively correlates with clinical outcome. Furthermore, we demonstrate that galectin-9 impairs CAR19 T-cell homeostasis and cytotoxicity. Notably, an engineered TIM-3–Fc decoy receptor, delivered either by primary T cells coadministered with CAR19 T cells or via a bicistronic all-in-one CAR19–TIM-3–Fc construct, improved the antileukemia efficacy and persistence of CAR19 T cells in B-ALL xenograft models. Mechanistically, CAR19–TIM-3–Fc T-cell treatment promotes the in vivo expansion of transduced and bystander effector and memory T cells, as determined by spectral flow cytometry. Collectively, these TIM-3–Fc decoy–armored CAR19 T cells offer a promising therapeutic strategy for patients with R/R B-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Madrid, Spain.
- Red Española de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain.
- Cancer Immunotherapy Unit, Immunology Department, Hospital Universitario 12 Octubre, Madrid, Spain.
- Immuno-Oncology and Immunotherapy Group, Biomedical Research Institute 12 de Octubre (i+12), Madrid, Spain.
- Cancer Immunotherapy Clinical Research Unit, Hospital 12 de Octubre-Centro Nacional de Investigaciones Oncologicas, Spanish National Cancer Research Centre, Madrid, Spain.
- Department of Clinical Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Aïda Falgàs, Samanta Romina Zanetti, Laura Rubio-Pérez, Alba Martínez-Moreno, Meritxell Vinyoles, Mercedes Guerrero-Murillo, Narcís Fernández-Fuentes, Néstor Tirado, Carla Panisello, Talia Velasco-Hernandez, Andrea Mayado, Alba Pérez-Pons, Eulalia Genescà, Josep-Maria Ribera, Mireia Camos, José Luis Fuster, Manel Juan, Ronald W Stam, Sergi Querol, Pablo Velasco, Valentín Ortiz-Maldonado, Nuria Martínez-Cibrián, Julio Delgado, Alberto Orfao, Luis Álvarez-Vallina, Clara Bueno
Zitieren
APA
Falgàs, A., Lázaro-Gorines, R., Zanetti, S. R., Rubio-Pérez, L., Martínez-Moreno, A., Vinyoles, M., Guerrero-Murillo, M., Fernández-Fuentes, N., Roca-Ho, H., Tirado, N., Panisello, C., Velasco-Hernandez, T., Mayado, A., Pérez-Pons, A., Genescà, E., Ribera, J. M., Ribera, J., Camos, M., Ramírez-Orellana, M., …, & Menéndez, P. (2025). A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood.2024025440
Vancouver
Falgàs A, Lázaro-Gorines R, Zanetti SR, Rubio-Pérez L, Martínez-Moreno A, Vinyoles M, et al. A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Blood. 2025. doi:10.1182/blood.2024025440
BibTeX
@article{Falgs2025,
author = {Falgàs, Aïda and Lázaro-Gorines, Rodrigo and Zanetti, Samanta Romina and Rubio-Pérez, Laura and Martínez-Moreno, Alba and Vinyoles, Meritxell and Guerrero-Murillo, Mercedes and Fernández-Fuentes, Narcís and Roca-Ho, Heleia and Tirado, Néstor and Panisello, Carla and Velasco-Hernandez, Talia and Mayado, Andrea and Pérez-Pons, Alba and Genescà, Eulalia and Ribera, Josep-Maria and Ribera, Jordi and Camos, Mireia and Ramírez-Orellana, Manuel and Anguita, Eduardo and Ballerini, Paola and Fuster, José Luis and Juan, Manel and González-Navarro, Europa Azucena and Locatelli, Franco and Stam, Ronald W and Querol, Sergi and Velasco, Pablo and Ortiz-Maldonado, Valentín and Martínez-Cibrián, Nuria and Delgado, Julio and Orfao, Alberto and Álvarez-Vallina, Luis and Bueno, Clara and Menéndez, Pablo},
title = {A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia},
journal = {Blood},
year = {2025},
doi = {10.1182/blood.2024025440}
}
EUVIMED